Pathalys Pharma

aid: pathalys-pharma
name: Pathalys Pharma
description: Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company headquartered at 4000 Center
  at North Hills Street, Raleigh, North Carolina, in the Research Triangle Park region. It was created with initial funding
  from Catalys Pacific and the DaVita Venture Group to be a multi-asset biopharmaceutical company focused on the needs of
  patients with end-stage kidney disease, and it develops advanced therapeutics addressing unmet needs in the management of
  late-stage chronic kidney disease (CKD). Its lead asset is upacicalcet, a novel non-peptide calcimimetic delivered intravenously
  by pre-filled syringe at the end of a hemodialysis session for the treatment of secondary hyperparathyroidism (SHPT) in
  patients with end-stage kidney disease on hemodialysis; it is an investigational product candidate in the United States,
  subject to FDA review. Pathalys raised $150 million in secured product financing and equity led by Abingworth in January
  2023 alongside a development collaboration with Launch Therapeutics to run the pivotal PATH Phase 3 program, and closed
  an oversubscribed $105 million Series B in August 2024 to fund NDA submission and pre-commercialization. Pathalys runs no
  developer program and publishes no product API; the only machine-readable surface it exposes is the anonymously readable
  WordPress REST content API behind pathalys.com, which serves the corporate site, the news and scientific-updates stream,
  and the media library.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: open
  trial: false
  try_now: false
  public: true
  gated: none
  gated_source:
  - onboarding
  label: Open access
  confidence: medium
  source:
  - authentication
  - rate-limits
  - security
  generated: '2026-11-02'
  method: derived
image: https://pathalys.com/wp-content/uploads/2021/09/pathalys_logo.svg
url: https://raw.githubusercontent.com/api-evangelist/pathalys-pharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Nephrology
- Chronic Kidney Disease
- Clinical Trials
- Life Sciences
- content-api
tags_raw:
- Company
- pharmaceuticals
- biotechnology
- nephrology
- chronic-kidney-disease
- clinical-trials
- life-sciences
- content-api
apis:
- aid: pathalys-pharma:pathalys-com-website-wordpress-rest
  name: Pathalys Pharma Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Pathalys Pharma website at pathalys.com: the route index of
    the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://pathalys.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://pathalys.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://pathalys.com/
- type: Team
  url: https://pathalys.com/team/
- type: News
  url: https://pathalys.com/news/
- type: Science
  url: https://pathalys.com/scientific-updates/
- type: Blog
  url: https://pathalys.com/news/
- type: BlogRSS
  url: https://pathalys.com/feed/
- type: Contact
  url: https://pathalys.com/contact/
- type: Support
  url: https://pathalys.com/contact/
- type: PrivacyPolicy
  url: https://pathalys.com/privacy-policy/
- type: TermsOfService
  url: https://pathalys.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/pathalys
- type: SecondaryMarket
  url: https://forgeglobal.com/pathalys-pharma_stock/
- type: Documentation
  url: https://developer.wordpress.org/rest-api/
- type: Authentication
  url: authentication/pathalys-pharma-authentication.yml
- type: Conventions
  url: conventions/pathalys-pharma-conventions.yml
- type: Conformance
  url: conformance/pathalys-pharma-conformance.yml
- type: ErrorCatalog
  url: errors/pathalys-pharma-problem-types.yml
- type: Lifecycle
  url: lifecycle/pathalys-pharma-lifecycle.yml
- type: DataModel
  url: data-model/pathalys-pharma-data-model.yml
- type: DomainSecurity
  url: security/pathalys-pharma-domain-security.yml
- type: Plans
  url: plans/pathalys-pharma-plans-pricing.yml
- type: RateLimits
  url: rate-limits/pathalys-pharma-rate-limits.yml
- type: LLMsTxt
  url: llms/pathalys-pharma-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-pointer-verification:
  checked: '2026-08-26'
  method: HTTP GET with a browser User-Agent, following redirects
  results:
  - url: https://pathalys.com/
    status: 200
  - url: https://pathalys.com/team/
    status: 200
  - url: https://pathalys.com/news/
    status: 200
  - url: https://pathalys.com/scientific-updates/
    status: 200
  - url: https://pathalys.com/contact/
    status: 200
  - url: https://pathalys.com/privacy-policy/
    status: 200
  - url: https://pathalys.com/terms-of-use/
    status: 200
  - url: https://pathalys.com/feed/
    status: 200
  - url: https://www.linkedin.com/company/pathalys
    status: 200
  - url: https://developer.wordpress.org/rest-api/
    status: 200
  - url: https://pathalys.com/wp-json/
    status: 200
  - url: https://forgeglobal.com/pathalys-pharma_stock/
    status: 403
    note: Bot challenge, not a dead page — Forge Global fronts its company pages with an edge policy that refuses non-browser
      clients. Retained as SecondaryMarket (the harvest source), not as Website. The company's real website is https://pathalys.com/,
      which the stub previously did not carry.
x-enrichment:
  date: '2026-08-26'
  status: enriched
  artifacts_added: 22
  pass: local-v1